Risk Factors Update Summary

• The company is initiating four to five potentially registrational programs for IMVT - 1402 by March 31, 2025, and trials in ten indications by March 31, 2026.
• Added the requirement for a valid transfer mechanism for personal information transfers, impacting operations.
• The FDA approved VYVGART (efgartigimod alfa and hyaluronidase-qvfc) for gMG treatment.
• Increased risks due to severe ransomware attacks and potential interruptions in operations.
• The FDA accepted for priority review a supplemental BLA for VYVGART Hytrulo for CIDP.
• Enhanced cybersecurity risks due to increased cyberattacks following hostilities, posing threats to data.
• The FDA approved RYSTIGGO (rozanolixizumab-noli) for gMG treatment in adults.
• Expanded risks related to dependence on third parties for manufacturing capabilities and product commercialization.
• The FDA accepted for priority review a supplemental BLA for VYVGART Hytrulo for CIDP.
• Added potential tax obligations increase due to the adoption of Pillar Two proposal.
• The FDA approved ULTOMIRIS (ravulizumab-cwvz) for gMG treatment in April 2022.
• The FDA approved ZILBRYSQ (zilucoplan) for gMG treatment in October 2023.